U.S. pharma huge copyright scrapped two experimental weight loss drugs final yr—a once-everyday capsule, lotiglipron, due to elevated liver enzymes plus a two times-day by day tablet, danuglipron, resulting from solid side effects—but CEO Albert Bourla has stated the company is set to “play and get” in the obesity House and in July the comp